(PharmaNewsWire.Com, June 10, 2017 ) According to the report “Global Acute Ischemic Stroke Diagnosis and Treatment Market,” published by Market Data Forecast, the global market is projected to reach USD 2508 million by 2020 from USD 1814 million in 2015, at a CAGR of 6.7%.
Acute ischemic stroke is an emergency. Approximately 2 million neurons are lost during each minute of stroke. Intravenous tissue plasminogen activator improves the likelihood of a good outcome. However, benefit is heavily time dependent. Patients treated within 90 minutes of symptom onset have better outcomes than those treated beyond that point. Rapid evaluation and management are key, and a minimum number of tests should be obtained before management. Different imaging studies, including computed tomography, magnetic resonance imaging, computed tomographic angiography, magnetic resonance angiography, and perfusion studies, are useful for evaluation of acute stroke. Trade-off exists between studies, such as better resolution versus greater delay. There is no evidence at present to suggest that additional imaging sequences improve patient outcomes. Intra-arterial management has yet to be proven beneficial to patients who have had strokes. Emergent stenting and sonothrombosis are of uncertain value. Aggressive blood pressure lowering should be avoided early after ischemic stroke. Anticoagulation with heparin or heparinoids is of no benefit to the majority of patients with strokes, and there does not appear to be a role for corticosteroids. Emergent surgical decompression with hemicraniectomy may be lifesaving for patients with large hemispheric or posterior fossa infarctions who become drowsy.
The factors influencing the Global Market for Acute Ischemic Stroke Diagnosis and Treatment Market, either positively or negatively are presented in the DROC analysis. Rising prevalence of acute ischemia stroke cases are driving the global demand for surgical procedures in acute stroke treatment. Technological advancements in surgical procedures along with rising aging population, increased demand for minimally invasive procedures and growth in healthcare spending are the other major factors driving the growth of Global Acute Ischemic Stroke diagnosis and treatment market on the other side excessive usage of medication for the treatment of ischemic stroke and high cost of surgical procedures are hindering the growth of the market.
For granular level understanding, the Acute Ischemic Stroke Diagnosis and Treatment Market is segmented based on the following categories with Market Size Estimations and Y-o-Y Forecasts presented for each sub-segments.
• By Diagnostic Type o Computed Tomography o Magnetic Resonance Imaging o Ultrasound o Cerebral angiography o Nuclear Imaging
• By Surgery Type o Carotid Endarterectomy o Angioplasty o Endovascular Mechanical Thrombectomy
On the Basis of geography global Acute Ischemic Stroke Diagnosis and Treatment Market is segmented into North America, Europe, Asia-Pacific, Latin America and Africa & Middle-East. North America is the largest market for Acute Ischemic Stroke Diagnosis and Treatment and is estimated to continue its strong hold of the market owing to favourable government initiatives, technological innovations and increasing demand for ischemic stroke products. Asia-Pacific is estimated to be a hopeful market for acute ischemic stroke diagnosis owing to increasing incidence of ischemic stroke cases in the region. Manufacturers are expanding their operations in Asia-Pacific region as these regions hold immense potential for the market growth.
• North America Acute Ischemic Stroke Diagnosis and Treatment Market • Europe Acute Ischemic Stroke Diagnosis and Treatment Market • Asia-Pacific Acute Ischemic Stroke Diagnosis and Treatment Market • Latin America Acute Ischemic Stroke Diagnosis and Treatment Market • Middle East and Africa Acute Ischemic Stroke Diagnosis and Treatment Market
Some of the major companies covered in the report are Abbott Laboratories, Covidien plc, Philips Healthcare, Johnson & Johnson, Penumbra, Inc., GE Healthcare, Siemens Healthcare, Stryker Corporation (Concentric Medical, Inc.) and Hitachi, Ltd.
The Acute Ischemic Stroke Diagnosis and Treatment Market study offers the following deliverables: • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the geographical areas in which this industry is blooming • Segment-level analysis on basis of product type, application, colour along with market size forecasts and y-o-y estimations to detect key areas of industry growth in detail • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics • Study of macro and micro environmental factors that effect the global market presented in an extensive strategic analyses section containing PESTLE and Porter’s Five Forces Analyses • A comprehensive listing of key market players along with company overview, product portfolios, key financial information (subjected to availability), SWOT analysis and analyst overview to study and sustain the market environment • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies • Expertly devised Market Outlook along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
